DUBLIN--(BUSINESS WIRE)--The "Osteosarcoma
- Pipeline Review, H2 2018" drug pipelines has been added to ResearchAndMarkets.com's
offering.
Osteosarcoma - Pipeline Review, H2 2018,
provides comprehensive information on the therapeutics under development
for Osteosarcoma (Oncology), complete with analysis by stage of
development, drug target, mechanism of action (MoA), route of
administration (RoA) and molecule type.
The guide covers the
descriptive pharmacological action of the therapeutics, its complete
research and development history and latest news and press releases.
The Osteosarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Osteosarcoma and features dormant and discontinued projects.
The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 22, 8, 1, 23 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 2, 2, 2 and 4 molecules, respectively.
Osteosarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Companies Featured
- Advenchen Laboratories LLC
- Amgen Inc
- AntiCancer Inc
- Arrowhead Pharmaceuticals Inc
- Autolus Therapeutics Plc
- AVEO Pharmaceuticals Inc
- Bayer AG
- Bellicum Pharmaceuticals Inc
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb Co
- Cellectar Biosciences Inc
- Cellestia Biotech AG
- Cellmid Ltd
- CorMedix Inc
- Eisai Co Ltd
- Endocyte Inc
- Exelixis Inc
- Intezyne Inc
- Ipsen SA
- Isofol Medical AB
- Jiangsu Hengrui Medicine Co Ltd
- MacroGenics Inc
- Mateon Therapeutics Inc
- MD Biosciences GmbH
- Merck & Co Inc
- Merck KGaA
- Nektar Therapeutics
- Novartis AG
- Oncolys BioPharma Inc
- Ono Pharmaceutical Co Ltd
- Pfizer Inc
- Sorrento Therapeutics Inc
- Teijin Pharma Ltd
- Tyme Technologies Inc
-
and more...
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/h2d3t6/osteosarcoma?w=4
